Are you looking to ensure compliance to the latest demanding regulations? Do need to be able to easily demonstrate control of your data? With Thermo Scientific™ Chromeleon™ CDS software you can rest assured.
Are you looking to ensure compliance to the latest demanding regulations? Do you need to be able to easily demonstrate control of your data? With Thermo Scientific™ Chromeleon™ CDS software you can rest assured. Delivering a comprehensive set of compliance tools, sequence-level data organization, and with audit trails tracking all actions in the software - including CDS-related external events – Chromeleon software allows you to defend your data with ease and utmost confidence, allowing you to focus on the important work of your lab.
From workstation to global deployment, Chromeleon software delivers compliance across your chromatography operation and throughout your enterprise − from research to routine quality testing − connecting people, instruments and other laboratory software, while delivering proven productivity gains for faster return on investment.
Visit resource center
Email: kris.ben-jamin@thermofisher.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.